CD274 and small cell lung carcinoma: The KEYNOTE-604 study evaluated the efficacy of pembrolizumab plus EP in previously untreated ES-SCLC, revealing comparable HRs for PFS and OS between the PD-L1 combined positive score (CPS) ≥ 1 and PD-L1 negative subgroups [36].